We are pleased to announce that BIOCIUS Life Sciences is now part of Agilent. BIOCIUS’ RapidFire drug screening technology coupled with our industry-leading TOF, Q-TOF, and triple quadrupole LC/MS systems enables Agilent to offer the most efficient mass spec-based drug screening solutions for the pharmaceutical and clinical markets. Together we will provide you with the unsurpassed ability to increase the effectiveness and reduce the cost of drug discovery and compound identification.
BIOCIUS’ RapidFire Technology:
More about the BIOCIUS Life Sciences Acquisition:
Agilent Resources:
|